Diagnoses and treatments of pleomorphic xanthoastrocytoma: a clinical analysis of 25 cases
10.3760/cma.j.cn115354-20200630-00522
- VernacularTitle:25例颅内多形性黄色星形细胞瘤临床病例分析
- Author:
Ting YU
1
;
Honghai YOU
;
Fuxiang CHEN
;
Wenzhong MEI
;
Xiyue WU
;
Dezhi KANG
Author Information
1. 福建医科大学附属第一医院神经外科，福州 350005
- Keywords:
Pleomorphic xanthoma;
Imaging feature;
Pathology;
Prognosis
- From:
Chinese Journal of Neuromedicine
2021;20(1):61-64
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical, imaging and pathological characteristics of pleomorphic xanthoastrocytoma (PXA), and to explore the effective treatment of PXA.Methods:A total of 25 patients with PXA admitted to our hospital from July 1, 2012 to December 1, 2019 were chosen in our study. Their clinical manifestations, imageology features, pathology features, treatments, and prognoses were retrospectively analyzed.Results:Headache ( n=12) and epilepsy ( n=8) were the most common first symptoms in 25 patients. The tumors in 8 patients were located in the parietal lobe, 6 were in the temporal lobe, and 6 were in the frontal lobe. Among the pathological results, the average positive rate of cell proliferation antigen Ki-67 and P53 in patients with WHO grading II was 6.4% and 21.2%, respectively; the average positive rate of Ki-67 and P53 in patients with WHO grading III was 22.2% and 48.3%, respectively. Synaptophysin protein was confirmed in 12 of the 15 patients. Twenty patients were followed up for 31 months after surgery; 19 survived; 9 had no tumor recurrence or residue, including 8 with WHO grading II and one with WHO grading III. Conclusion:Pathological result play an important role in PXA diagnosis; the prognosis of patients with WHO grading II is obviously better than that of patients with WHO grading III.
